Matt Lunning, D.O. FACP
Matthew Lunning D.O., FACP, is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center. Dr. Lunning also is Associate Vice Chair of Research for the Department of Internal Medicine, Medical Director of the Clinical Research Center (CRC), and Medical Director of Cellular Therapies.
He received his medical degree from Des Moines University in 2006. Dr. Lunning completed his internal medicine residency at UNMC where he served as Chief Medical Resident. He completed his Hematology/Oncology fellowship and served as the Hematology Chief Fellow at Memorial Sloan-Kettering Cancer Center. Dr. Lunning returned to UNMC in 2013 and has been active in clinic research, research mentoring, education, and patient care. Dr. Lunning was the recipient of the Distinguish Scientist Award in 2019.
Dr. Lunning has served on several National Comprehensive Cancer Network’s guidelines committees including the Immunotherapy Toxicity & T-cell lymphoma panels. He has served as an invited member of ASCO’s Cancer Education Committee on the Non-Hodgkin Lymphoma. He is the co-organizer of the Pan Pacific Lymphoma Conference.
Financial relationships
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:AbbvieTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Astra ZenecaTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:BMSTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:CaribouTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Daiichi SankyoTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:Fate TherapeuticsTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:GenentechTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:GenMabTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:IpsenTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:JanssenTopic:ConsultantDate added:02/01/2024Date updated:02/01/2024